Why the study?
Minimally invasive mitral valve surgery is increasingly performed despite longer procedural times, prompting an analysis of clinical outcomes and secondary organ function effects compared to conventional surgery.
Does minimally invasive mitral valve surgery improve clinical outcomes and organ function compared to conventional sternotomy in patients undergoing MV surgery?
Does minimally invasive mitral valve surgery improve clinical outcomes and organ function compared to conventional sternotomy in patients undergoing MV surgery?
Minimally invasive mitral valve surgery provides non-inferior clinical outcomes and repair quality compared to sternotomy, with lower systemic inflammation but increased risk of rhabdomyolysis due to longer procedural times.
Answers are grounded in this paper and cite their sources.
Minimally invasive MV surgery shows comparable short-term outcomes; leaves open need for randomized confirmation of organ effects.
BACKGROUND: Minimally invasive mitral valve (MV) surgery (MIVT) is increasingly performed with excellent clinical outcome, despite longer procedural times. This study analyzes clinical outcomes and effects on secondary organ functions in a propensity-matched comparison with conventional MV surgery. METHODS AND RESULTS: Out of 439 patients undergoing MV surgery from January 2005 to May 2017, 233 patients were included after propensity-matching: 90 sternotomy patients and 143 MIVT patients. Endpoints focused on survival, quality of MV repair, and organ function effects through analysis of biomarkers and functional parameters. Regardless of longer cardiopulmonary bypass (sternotomy: 101(IQR33) min-MIVT:143(IQR45) min, p < .001) and cardioplegic arrest times(sternotomy: 64(IQR25) min-MIVT:90(IQR34) min, p < .001), no differences in survival nor complication rate were found. Effect on renal function(creatinine, p = .751 - ureum, p = .538 - glomerular filtration, p = .848), myocardial damage by troponine I level (sternotomy:1.8 ± 3.9 ng/ml - MIVT:1.2 ± 1.3 ng/ml, p = .438) and prolonged ventilatory support >24 h (sternotomy:5.5% - MIVT:8.4%, p = .417) were comparable. The systemic inflammatory reaction by postoperative C-reactive protein count was markedly lower for MIVT(p < .001). Increased rhadomyolysis was found after MIVT surgery, based on a significant elevation of creatinine-kinase levels(sternotomy: 431 ± 237 U/L - MIVT: 701 ± 595 U/L, p < .001). CONCLUSION: Despite an inherent learning curve, minimally invasive MV surgery guarantees a clinical outcome and MV repair quality, at least non-inferior to those of MV surgery via sternotomy. Notwithstanding longer cardiopulmonary bypass and cardiac arrest times, the impact on secondary organ function is negligible, except for a lower systemic inflammatory response. The postoperative increase of CK-enzymes suggestive for enhanced rhabdomyolysis needs to be accounted for when procedural times tend to exceed the critical time threshold for severe limb ischemia.
No takes yet. Share an insight, caveat, or question.
Missault et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: